Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Adrenocorticotropic Hormone Gel Clear all

Conditions: Sarcoid Uveitis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: John Huang, MD; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Hamden, Connecticut

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 38
States / cities: Homewood, Alabama • Tucson, Arizona • Colorado Springs, Colorado + 35 more

Conditions: IgA Nephropathy, Proteinuria
Interventions: Acthar 80 unit injection; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoidosis
Interventions: Acthar gel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: H.P. Acthar® Gel; Drug
Lead sponsor: Mamatha Pasnoor, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more

Conditions: Dermatomyositis, Polymyositis
Interventions: Adrenocorticotropic Hormone Gel; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Great Neck, New York • Pittsburgh, Pennsylvania

Conditions: Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions: Acthar; Drug
Lead sponsor: Greater Boston Medical Associates; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milford, Massachusetts

Conditions: Sarcoidosis, Pulmonary Sarcoidosis
Interventions: Acthar gel; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: CNS Sarcoidosis
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Keratitis
Interventions: Acthar; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more

Conditions: Dermatomyositis, Juvenile Dermatomyositis
Interventions: H.P. Acthar Gel; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Repository corticotropin injection; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 14 more

Conditions: Keratoconjunctivitis Sicca
Interventions: repository corticotropin injection; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: End Stage Renal Disease
Interventions: Acthar Gel; Drug
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Canfield, Ohio

Conditions: Proteinuria, Idiopathic Membranous Nephropathy
Interventions: Repository Corticotropin Injection, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Sacramento, California • Stanford, California • Jacksonville, Florida + 11 more

Conditions: Diabetic Nephropathy, Nephrotic Syndrome
Interventions: ACTH; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Sarcoidosis
Interventions: Repository Corticotropin Injection; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uveitis
Interventions: Acthar; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dry Eye Disease
Interventions: Corticotropin 80Unit/Ml Repository Injection; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rheumatoid Arthritis
Interventions: Repository corticotropin injection; Drug
Lead sponsor: Arthritis Treatment Center, Maryland; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions: ACTHAR Gel (adrenocorticotropic hormone); Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: ACTH, Placebo; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Cullman, Alabama • Medford, Oregon • Portland, Oregon + 2 more

Conditions: Multiple Sclerosis
Interventions: Acthar Gel; Drug
Lead sponsor: Tanner Foundation for Multiple Sclerosis; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

(ACTH) for the Treatment of Sarcoid Uveitis

Observational Registry of Acthar Gel for Participants With Multiple Sclerosis Relapse

Acthar on Proteinuria in IgA Nephropathy Patients

Use of CXCL9 as a Biomarker of Acthar Efficacy

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

Treatment of CNS Sarcoidosis With H.P. Acthar Gel

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis

Repository Corticotropin Injection in Keratoconjunctivitis Sicca

Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population

Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

ACTHAR Therapy for Central Nervous System Sarcoidosis

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

ACTH for Fatigue in Multiple Sclerosis Patients

Comprehensive Analysis of Relapse in Multiple Sclerosis